Riskpilot← Back to searchSign inGet full accessSjöstrand Biobusiness AB
ABDissolvedOrg 5590150164Business and other management consultancy activities · NACE 7022Est. 20150 employees
Revenue 2022
SEK 0
EBITDA margin
—
-224% vs 2021
Equity ratio
266.6%
Financial strength
Net profit 2022
SEK -31K
-224% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -31K | -224% |
| Net profit | SEK -31K | -224% |
| Total assets | SEK 84K | -73% |
| Equity | SEK 223K | -12% |
| Employees | 0 | — |
Legal name
Sjöstrand Biobusiness AB
Org number
5590150164
Legal form
Aktiebolag
NACE code
7022 · Business and other management consultancy activities
Founded
26 maj 2015
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanterna
Company purpose
Bolaget ska tillhandahålla managementtjänster, äga och förvalta värdepapper, kapitalförvaltning och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 511 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 397 | −107 | −66 | 25 | −31 |
| Depreciation & amort. | −220 | −0 | −0 | −0 | — |
| EBIT | 177 | −107 | −66 | 25 | −31 |
| Net financials | — | — | — | — | 0 |
| Profit before tax | 133 | −62 | −66 | 25 | −31 |
| Tax | −32 | −0 | −0 | −0 | — |
| Net profit | 101 | −62 | −66 | 25 | −31 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 728 | 364 | 287 | 307 | 84 |
| Equity | 357 | 295 | 228 | 254 | 223 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 325 | 69 | 59 | 54 | −139 |
| Total debt | 325 | 69 | 59 | 54 | −139 |
EBITDA margin
-3098300.0%
This company
15.8%
Market median
-19609594% vs market
20182022
Equity ratio
266.6%
This company
38.2%
Market median
+598% vs market
20182022
Return on equity
-13.9%
This company
18.4%
Market median
-176% vs market
20182022
Net profit margin
-3092500.0%
This company
8.1%
Market median
-38179112% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
-0.62×
This company
0.62×
Market median
+200% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
LE Audit | Audit | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2024 | |
| Deputy Board Member | 2024 | |
| Deputy Board Member | 2024 | |
| Former (2) | ||
| Board of Directors | 2022 – 2024 | |
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sjöstrand Biobusiness AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars-Erik Engberg | Audit | 0 companies |
| Lena Birgitta Killgren Jonsson | Deputy Board Member | 0 companies |
| Inger Margareta Dahle | Board of Directors | 0 companies |
| Björn Magnus Sjöstrand | Board of Directors | 0 companies |
| Bengt Junior Niklas Nygårds | Deputy Board Member | 0 companies |
| Malin Sjöstrand | Deputy Board Member | 0 companies |
| Ulrika Margareta Ahlholm | Deputy Board Member | 0 companies |